 Home > Medical News > Latest Medical News > ALS new drug research and development both suffered setbacks: Biogen/Ionis terminated the phase I trial of Amylyx's drug listing, which was questioned by FDA

ALS new drug research and development both suffered setbacks: Biogen/Ionis terminated the phase I trial of Amylyx's drug listing, which was questioned by FDA

 Last Update: 2022-04-21
 Source: Internet
 Author: User

Tags

drug wet

food drug administration

stress test drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationAspirin

Amyotrophic lateral sclerosis (ALS), also known as ALS, motor neuron disease, Charcot disease, Lou Gehrig's disease, etc.

On March 28, Biogen and its partner Ionis Pharmaceuticals released the first-line results of the Phase I clinical trial of BIIB078

BIIB078 is an investigational antisense oligonucleotide drug for the treatment of C9orf72-related ALS

According to the results disclosed by the company, BIIB078 was well tolerated and its adverse events (AEs) were mostly mild to moderate in severity

The relevant person in charge of Ionis said that the scientific community believes that there are many mechanisms by which the C9orf72 gene causes disease, and in this test, it is believed that the C9orf72-related ALS disease mechanism is caused by the related toxicity of RNA and corresponding dipeptide repeat sequences

Meanwhile, Amylyx Pharmaceuticals is also holding back progress on ALS drugs

Amylyx stock fell sharply, down more than 40%, within half an hour of the FDA's announcement on the news

Still, despite concerns about the data, the FDA may still eventually consider approving the ALS drug due to its high demand

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.